Mucormycosis, COVID-19, and immunosuppression – The three sides of similar triangle

Abstract

Introduction: More than two years into the COVID 19 pandemic, medical fraternity each day is facing renewed challenges. Mucormycosis has historically been prevalent in the various parts of world but did not had any diagnostic opportunity before the turn of 20th century. Immunosuppression in any form was always and will forever be the most important ingredients in this disease recipe. Minimally invasive diagnoses with aggressive antimicrobials in addition to the removal of immunosuppression factor are the golden standard of treatment, as oral and maxillofacial surgeons we acknowledge that surgical debridement and various other relatively newer adjunctive therapies have overall reduced the fatal outcomes for such a lethal disease. Aim: This review article focuses on gathering data in relation to immunosuppression due to whatsoever reason and pathogenesis, management, and chance of positive prognosis for patient suffering from mucormycosis . Including surgical and prosthetic options which ascertain descent quality of life for the patient. Materials and Methods: Existing data compilation including the latest research and co-relation of various types of immunosuppression as a nidus for mucormycosis, including the role of novel covid-19 from all relevant electronic databases. Results: Definite co-relation has been stablished for diabetes melitus and covid-19 and speculative co-relation for various types of malignancy and various conditions. Discussion: A strong immunity is an antagonist for mucormycosis, and new advances in field of medicine and surgery have changed the grim look of past where this disease had a 50% mortality rate. Conclusion: Existing literature supports immunosuppression in any form as a nidus for mucormycosis, still further, elaborate research and development is required for identifying the particular cocktail for different diseases process.